Refractory Angina Pectoris
14
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina
IMR Evaluation in Patients with Coronary Sinus Reducer Implantation (INROAD Study)
Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris
Efficacy of Spinal Cord Stimulation in Patients With Refractory Angina Pectoris
Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
CoROnary SinuS Reducer implantatiOn for ischemiA reDuction
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients
Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease
Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris
Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris
Efficacy of Extracorporeal Shockwave Myocardial Revascularization
Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris
Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris